A Randomized Phase I Study to Assess the Pharmacokinetics, Tolerability, Efficacy and Pharmacodynamics of Three Dosing Schedules of Oral Rigosertib in Transfusion-dependent, Low, Intermediate 1, or Intermediate-2 Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2018
Price : $35 *
At a glance
- Drugs Rigosertib (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Onconova Therapeutics
- 31 Jul 2018 Planned End Date changed from 1 Oct 2018 to 1 Nov 2019.
- 31 Jul 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Aug 2019.
- 02 May 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.